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Background: Intestinal polyps may further develop into colon cancer; the pathogenesis is not clear. The p53 gene
is an important anti-cancer gene in the body, which is suppressed in cancer. The ubiquitin E3 ligase A20 (A20) plays
a role in regulating the activities of epithelial cells. This study was designed to investigate the role of the colon
polyp epithelium-derived A20 in the pathogenesis of colon cancer.
Results: Eighty-eight colon cancer patients and 136 colon polyp patients were recruited into this study. Human
colon cancer tissue, the epithelium of adenomas polyp and hyperplastic polyp showed high levels of A20, which
had a positive correlation with the cancerous tendency of colon polyps. The levels of A20 were much higher in the
adenomas and hyperplastic polyps than that in the inflammatory polyps; the latter showed less cancerous
tendency. A20 bound p53 to form complexes in colon cancer tissue and colon polyps. Over expression of A20
suppresses P53 protein levels in the HEK293 cells.
Conclusions: A20 may play an important role in the cancerous tendency of colon polyposis.
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Colon cancer is one of the leading causes of human death
in the world [1,2]. The study in the pathogenesis of colon
cancer advanced rapidly in recent years; still the etiology of
colon cancer is unclear. The community based colon can-
cer screening contributes to the early diagnosis of colon
cancer, which has markedly increased the therapeutic effect
of colon cancer [3]. The survival rate of colon cancer is af-
fected by the local recurrence, lymphatic metastasis and
hematogenous dissemination [4]. Immune system and mo-
lecular deregulation are considered as important factors in
tumor recurrence and tumor metastasis [5,6].
Colon polyps are a common disorder in human. It is
estimated, after 60 years of age, more than 50% people
suffers from colon polyps [7]. The phenotypes of colon
polyps include hyperplastic polyps, inflammatory polyps
and adenomas polyps. Certain types of colon polyps* Correspondence: ZiqiZhang45@163.com
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reproduction in any medium, provided the orgrow large and fast and become cancerous [8]. Aden-
omas polyps account about 50% colon polyps [9]. How
the polyp epithelium differentiate into cancer tissue is
still unclear.
P53 protein is a cancer suppressor protein; it is encoded
by the TP53 gene in human. P53 protein is a crucial regu-
lator of cell cycle and apoptotic process in the cell; it func-
tions in the cancer prevention [10]. The gene expression
disorders of p53, including mutations in exon 7 [11],
codon 245 [12], conserved areas [13], and the L3 struc-
tural domain [14], are associated with the pathogenesis of
colon cancer. To date, the factors causing p53 suppression
are still to be investigated.
Recent studies indicate the ubiquitin E3 ligase A20
(A20, in short) plays a critical role in the immune regu-
lation as well as in associating with the pathogenesis of
cancer [15]. By promoting the tolerogenicity in dendritic
cells, A20 plays a role in the induction of immune toler-
ance, which is a crucial drawback in cancer prevention
in the body. A20 and other ubiquitin E3 ligases may be
involved in the suppression of p53 function [16]. In thisThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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colon polyps had high levels of A20, which was signifi-
cantly correlated with the tumorigenesis of colon polyps.
Methods
Reagents
The antibodies of A20, p53 were purchased from Santa
Cruz (Shanghai, China). The reagents for real time RT-PCR,
Western blotting, A20 over expression and immune precipi-
tation were purchased from Invitrogen (Shanghai, China).
The HEK293 cells were purchased from China Cell Line
(Shanghai, China). MG132 was purchased from Sigma Al-
drich (Shanghai, China). Recombinant A20 and p53 proteins
were purchased from R&D Systems (Shanghai, China).
Patients
Patients with colon cancer, non-cancer colon polyp and
IBS (irritable bowel syndrome) were recruited into this
study from 2005 to 2012 at our department. The diagno-
sis was carried out by their physicians and pathologists.
After diagnosis, the colon polyps were removed by their
surgeons under colonoscopy. The colon cancer tissue and
polyp epithelium (dissected under an analytical micro-
scope) were collected in the operation room. Biopsies
from IBS patients were obtained under colonoscopy. The
tissue was processed for the RNA and protein extraction
immediately after collection; the extracts were stored at -
80°C until use. The using human tissue in this study was
approved by the Human Research Ethic Committee of the
China PLA General Hospital. The written, informed con-
sents were obtained from each patient.
Follow-up
All the patients with colon polyps were required to do
follow-up visits every three months after the colonos-
copy surgery.
Quantitative real time RT-PCR (qRT-PCR)
Total RNA was extracted from the collected cancer tis-
sue and polyp epithelium using Trizol reagent according
to the manufacturer’s instructions. Two micrograms of
RNA were reversely transcribed in a 20 μl reaction using
random primers and Transcriptor First Strand Synthesis
kit. SYBR green-based qRT-PCR was performed with a
Bio-Rad MiniOpticon™ Real-Time PCR Detection System.
Expression of target genes was normalized to β-actin
mRNA levels. The primers of A20 were: Forward: gagag
cacaatggctgaaca; reverse: tccagtgtgtatcggtgcat (NCBI: NM_
006290.2).
Western blotting
Equal amounts of total protein from each sample were
separated using SDS–PAGE and transferred to nitrocel-
lulose membranes. Membranes were then blocked with5% skim milk in TBST (Tris-buffered saline with Tween)
and incubated overnight with the primary antibodies
(0.5-1 μg/ml) at 4°C. Following washes with TBST, the
membranes were incubated with HRP-conjugated secondary
antibodies for 1 h at room temperature. The detection was
carried out using an enhanced chemiluminescence Western
blotting system.
Enzyme-linked immunoassay (ELISA)
The protein extracts or an irrelevant protein (bovine
serum albumin, BSA; using as negative controls), or re-
combinant A20 or p53 proteins, were added to micro
plates at 20 μg/ml (0.1 ml/well) in duplicate; the plate
was incubated overnight at 4°C. After blocking with 5%
skim milk for 1 h, the first antibodies against the target
proteins was added to the wells (at 10 ng/ml; incubated
for 1 h), and followed by incubating with horseradish
peroxidase (HRP)-conjugated secondary antibodies (5 ng/ml;
incubated for 1 h)”. Washing withTBST was performed after
each incubation. The formed immune complex in the
plate was developed by adding 3,3',5,5'-Tetramethylbenzidine
(TMB) for 20 min; the reaction was stopped by adding
25 μl 2 M H2SO4. The optical density (OD) of each
well was determined by a micro plate reader (Bio Tek,
Shanghai, China). The OD value of the negative con-
trols was subtracted from the OD values of each sam-
ple well. The results were calculated against the standard
curves. The sensitive limit for A20 was 2 pg/ml, and 5 pg/ml
for p53 respectively.
Immunohistochemistry
The colon tissue was obtained from 10 colon cancer pa-
tients and 10 IBS patients. The samples were processed
for cryosections and stained with anti-A20 antibodies.
The samples were observed with a confocal microscope.
Isotype IgG was used as a negative control.
Overexpression of A20
DNA fragments encoding A20 were generated by poly-
merase chain reaction (PCR) using the human source
(NCBI: NM_006290.2) sense primer (5′-cttaacggatccgcca
cctgccttgaccaggacttggg-3′) and antisense primer (5′-ggtg
gcgaccggttaatgttgactcttgtgaaa-3′) (ggatcc: BamHI; accggt:
AgeI; gccacc: Kozak sequence). DNAs were gel purified
and ligated into BamH I/Age1-digested pcDNA3.1. The
A20-plasmid was designated as the pA20. HEK293 cells
were transfected with pA20 or control plasmid (cpA20;
containing no A20 sequence) respectively, using the
Lipofectamine 2000 according to the manufacturer’s
protocols. On the next day, the cells were treated with
50 μg/ml ampicillin and exposed to fresh media containing
the same concentration of ampicillin every 3 days for 2-3
weeks. Individual drug-resistant clones were collected and
expanded for further identification.
Table 1 Demographic data of pateitns with colon cancer
Features Number of patients
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Immunoprecipitation was performed to detect the com-
plexes of A20/p53 using the Dynabeads® Protein G Im-
munoprecipitation Kit according to the manufacturer’s
instruction. The precipitation antibodies were either
anti-A20, or anti-p53, or isotype IgG. Proteins in the
immunoprecipitations were separated by SDS-PAGE.
The membrane was stained with either anti-A20 or
anti-p53.
Statistical analysis
All data were expressed as mean ± SD. The means were
compared between groups with one-way analysis of vari-
ance (ANOVA) and the Student t test. p value <0.05 was
considered significant.
Results
High levels of A20 and low levels of p53 in colon
cancer
Immune deregulation plays a role in the pathogenesis of
cancer [17]; recent reports indicate that A20 contributes
to immune regulation [18]. Whether A20 is involved in
the pathogenesis of colon cancer is unclear. Thus, we
collected 88 colon cancer tissue from the clinic (see
Table 1 for the demographic data). As shown by qRT-
PCR and Western blotting, the A20 levels were higher
in colon cancer tissue than that in the IBS colon tissue
(Figure 1A-B). The expression of p53 was also assessed
in all the samples. The results showed that the expres-
sion of p53 was significantly suppressed in colon cancer
tissue as compared with controls (Figure 1A, Figure 1C).
When reviewed the disease history, we noted that 32/88
(36.4%) cases also suffered from colon polyp. A correl-
ation assay was performed with the A20 levels of the
colon cancer tissue and their polyp history. The results
showed that the A20 levels were positively correlated
with the polyp history (r = 0.766, p < 0.01. Figure 1D). By
immunohistochemistry, we observed the expression of
A20 was mainly localized in the epithelial cells, which
was much stronger in cancerous tissue than that from
the IBS colon mucosa (Figure 1E).
Levels of A20 and p53 are correlated with recurrence of
colon polyp
Colon polyps have tendency to develop into colon
cancer. We then recruited 136 patients with non-
cancer colon polyp at the first diagnosis (the recurred
cases were excluded at recruitment). The colon polyps
were removed under colonoscopy. The levels of A20
in the polyp epithelium were assessed by ELISA. The
results showed that the levels of A20 in the polyp epi-
thelium were higher, p53 levels were lower, as com-
pared to controls (Figure 2A). All the patients were
followed-up three times a year. The follow-up datashowed that the polyp recurred in 59/136 (43.4%) pa-
tients (Figure 2B). Their colon polyps were removed
under colonoscopy again. The polyp epithelium was
also examined by ELISA for the levels of A20 and p53.
The results showed the levels of A20 were higher, p53
were lower, in the recurred polyp (polyp-2) than the
levels in the original polyp (polyp-1) (Figure 2A). We
then performed a correlation assay with the levels of
A20 and p53 in the polyp and the recurrence of the
original 136 patients. A significant positive correlation
was identified between the levels of A20 (r = 0.87, p < 0.01.
Figure 2C) or p53 (r = -0.67, p < 0.01. Figure 2D) and
the recurrence of colon polyps. We further analyzed the
relation between the phenotypes of the colon polyps and
the levels of A20 and p53. As shown by ELISA data, the
levels of A20 were higher, p53 were lower, in adenomas
and hyperplastic polyps than the inflammatory polyps
(Figure 2E).
Figure 2 A20 and p53 levels in colon polyps and rate of polyp relapse. A, the bars indicate the levels of A20 and p53 in colon polyp tissue
(assessed by ELISA). Polyp-1: Polyp samples were collected from 136 patients with colon polyposis. Polyp-2: Polyp samples were collected from 59
patients with relapsed polyposis. *, p < 0.05, compared with control (samples were obtained from IBS patients; see Figure 1). B, the bars indicate
the number of patients whose polyposis relapsed. The X axis indicate the time intervals when the polyposis relapsed. C-D, the dot plots present
the correlation between polyp history and A20 (C) or p53 (D) levels in polyp tissue with the raw data. E, the bars indicate the levels of A20 of
p53 in colon polyps of different pathological phenotypes. F, the bars indicate the A20 levels in colon polyps of different pathological types of
polyps. The X axis of E and F indicate the pathological types of colon polyps (the “1” indicates before the diagnosis of cancer; the “2” indicates
after the diagnosis of cancer). The data in bar graphs were presented as mean ± SD. *, p < 0.05, compared with control group (IBS group; see
Figure 1 in detail). #, p < 0.01, compared with adenomas group. Samples from individual patients were processed separately. Each experiment
was repeated 3 times. Cancerous: The colon polyp developed into cancer.
Figure 1 A20 levels in colon cancer tissue. Colon cancer tissue was collected from 88 patients with colon cancer. Control colon tissue was
collected from 10 patients with IBS (irritable bowel syndrome). A, the bars indicate the levels of A20 or p53 mRNA (by qRT-PCR). B and C, the
immune blots indicate the protein levels of A20 (B) and p53 (C). The bars below the immune blots indicate the integrated density of the
immune blots. The samples from different patients were processed individually (samples were processed in respect sample tubes in qRT-PCR and
respect sample wells in Western blotting). D, the dot plots indicate the correlation between the polyp history and A20 levels in the polyp tissue
(each dot represents one sample; some dots are overlapped). E, the representative confocal images indicate the A20 staining (in green; the red
color indicates the nuclearing staining) in cancerous tissue (E1) and IBS colon tissue (E2). E3 is an isotype control. *, p < 0.05, compared with the
control group. Samples from individual patients were processed separately.
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tendency
The 136 patients with colon polyp were followed up for
3-6 years. During this period, 45 (33.1%) patients were
diagnosed colon cancer. We analyzed the cancerous rate
of the pathological phenotypes of the colon polyps. The
results showed 4/79 (5.1%) inflammatory colon polyps,
14/21 (66.7%) hyperplastic and 27/36 (75.0%) adenomas
developed into colon cancer (Table 2). The A20 levels
were much higher in the cancerous group than that in
non-cancerous group (IBS group) both before and after
the diagnosis of cancer (Figure 2F). The data imply that
the levels of A20 in colon polyps were involved in the
pathogenesis of colon polyps.
A20 binds p53 protein in colon cancer
The data we presented so far imply that A20 may play a
role in the pathogenesis of colon cancer. The mechan-
ism is to be further elucidated. The p53 protein is an im-
portant molecule in the prevention of tumorigenesis. Based
on the above results, we wondered if A20 inhibited the
p53 protein in colon cancer cells. By immune precipi-
tation assay, we identified a complex of A20 and p53
in cancer cells as well as polyp epithelial cells with
high levels of A20, but not in the polyp epithelium
with low A20 levels (Figure 3).
A20 suppresses p53 protein
The finding of the complex of A20 and p53 in colon
cancer tissue implies that A20 may suppress p53 protein
in the cells. To test the hypothesis, we over expressed
A20 in HEK293 cells (Figure 4A); the expression of A20
significantly suppressed the levels of p53 in the cells
(Figure 4B). To further confirm the results, we added re-
combinant A20 to the HEK293 cell culture. The cellsTable 2 Demographic data of patients with colon polyp
Features Number of patients Developed into cancer





Inflammatory 79 (58.1%) 4 (5.1%)
Hyperplastic 21 (15.4%) 14 (66.7%)*




*, p < 0.01, compared to inflammatory group.were collected 48 h later. As shown by Western blotting,
A20 inhibited the expression in a dose-dependent man-
ner, which was not reversed by the proteasome inhibitor
MG132 (Figure 4C).
Discussion
The present study reports that high levels of A20 and
low levels of p53 were detected in colon cancer tissue
and colon polyps. The levels of A20 were significantly
correlated with the cancerous tendency of colon polyps.
By immune precipitation assay, we noted that A20
bound to p53 to form a complex. Over expression of
A20 significantly suppressed the expression of p53 in the
cells. It is well documented that colon polyps have high
tendency of tumorigenesis. After removing by surgery,
adenomas and hyperplastic colon polyps relapse often;
some of them eventually develop into colon cancer
[19-21]. Our data are in line with the previous studies
[19-21] by showing that more than 70% adenomas type of
colon polyps developed into colon cancer. The hyperplastic
colon polyps also have a high cancerous tendency as
observed in the present study. Among the recruited
patients, more than 50% colon polyps are inflamma-
tory phenotype; these colon polyps contain less A20 as
compared to other two phenotypes; also the cancerous
rate is much less.
Based on published data, A20 plays a role in the im-
mune regulation. The well-documented role of A20 in
the immune regulation is that A20 inhibits NF-κB acti-
vation [22]. NF-κB functions as an oncogene and the
link between inflammation and cancer [23]. Other re-
ports indicate that A20 plays an important role in the in-
duction of immune tolerance [24,25]. It seems that A20
has multiple functions depending on the cell types and
the micro environment. Recent reports indicate that intes-
tinal epithelial cells express A20, and A20 plays a crit-
ical role in epithelial cells’ basic functions such as the
antigen processing and the barrier function [26,27].
Considering that the original lesion location of colon
cancer and polyp is colon epithelial cells, we inferred
that A20 may play a role in these diseases. The results
have confirmed our hypothesis. High levels of A20
were detected in colon cancer and colon polyp epithelium.
The levels of A20 were correlated with the tumorigenesis
of colon polyps.
P53 protein is a critical molecule in the maintenance
of the cell homeostasis and prevention of tumorigenesis.
Cumulative reports have revealed that the expression of
p53 is suppressed in cancer tissue [28]. The TP53 gene
mutation is suggested as an important factor in the dys-
function of p53 that leads to tumorigenesis [11]. Our
study has expanded the studies of the p53 expression by
showing that the A20 binds to p53 to form complexes
in colon cancer tissue and colon polyp epithelium.
Figure 3 A complex of A20 and p53. Tissue protein was extracted from normal colon mucosa (control), colon cancer tissue (Cca) and colon
polyp epithelium (polyp). The extracts were immune precipitated (IP) by anti-p53 Ab (A, C) or anti-A20 Ab (B, D), and immune blotted (IB) with
anti-p53 Ab (A, D) or anti-A20 Ab (B, C). The immune blots indicate a complex of A20/p53 at 143 kDa. Iso pc Ab: The extracts from Cca and
polyp were mixed and were precipitated by isotype IgG using as a negative control; the isotype antibody of anti-P53 was used in the
experiments of panel A; the isotype antibody of anti-A20 was used in the experiments of panel B. The data represent 3 separate experiments.
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sion in the cells. On the other hand, MDM2 (Mouse
double minute 2 homolog) is a known E3 ligase for
p53. The function and regulation of MDM2 as a com-
ponent of a p53-dependent negative feedback loop has
formed a core paradigm in the p53 field [29]. Do
MDM2 and A20 play redundant roles in human colonFigure 4 Over expression of A20 suppresses p53 protein. A, the immu
HEK293 cells. pA20 (or pcDNA3.1): HEK293 cells were transfected with A20
B, the bars indicate the levels of p53 in HEK293 cells (by ELISA). A20-ov-e: H
controls. C, the immune blots indicate the p53 levels in the cell extracts of
doses (denoted below the blots) in the culture for 48 h. The data represencancer and colon polyps is an interesting point to be
further investigated.
Conclusions
High levels of A20 in colon cancer tissue and colon
polyp epithelium. Colon polyp epithelium with high A20
levels has the cancerous tendency.ne blots indicate A20 levels in HEK293 cell extracts. Control: Naïve
(or control) expression plasmid. The β-actin is an internal control.
EK293 cells with A20 over expression. *, p < 0.01, compared with naïve
HEK293 cells after treatment with exogenous A20 at the indicated
t 3 separate experiments. The data represent 3 separate experiments.
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